Pentraxin 3 as a novel diagnostic marker in neonatal sepsis.
Autor: | Fahmey SS; Department of Pediatrics, Beni-Suef University, Beni-Suef, Egypt., Mostafa N; Department of Clinical and Chemical Pathology, Beni-Suef University, Beni-Suef, Egypt. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of neonatal-perinatal medicine [J Neonatal Perinatal Med] 2019; Vol. 12 (4), pp. 437-442. |
DOI: | 10.3233/NPM-190261 |
Abstrakt: | Background: Neonatal sepsis is an important cause of morbidity and mortality especially in developing countries. As clinical manifestations of neonatal sepsis are nonspecific, early diagnosis and treatment remain a challenge. Pentraxin 3 (PTX3) is an acute-phase protein secreted by various cells in response to the proinflammatory signals. Our aim was to investigate the diagnostic value of PTX3 in neonatal sepsis. Methods: We studied 90 neonates; 60 with culture-proven sepsis and 30 healthy neonates as a control group. Serum levels of PTX 3 were measured by ELISA. Results: Neonates with sepsis had significantly higher levels of PTX 3 as compared to controls (p < 0.001). Diagnostic cutoff value of PTX 3 was 5.6 μg/L with a sensitivity of 98.3% and a specificity of 96.7%. PTX 3 was significantly increased in nonsurvivors when compared to survivors (p < 0.001). PTX3 had better sensitivity when compared with CRP. Conclusion: PTX 3 could be used as a new biomarker of neonatal sepsis with high sensitivity and specificity. |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |